Summary
Baroreceptor activation therapy improves quality of life, exercise capacity, and potentially the burden of heart failure hospitalizations in patients with functional class III heart failure with reduced ejection fraction who are on optimal medical and/or device therapy, with pronounced benefit in patients who are not treated with cardiac resynchronization therapy.
- baroreceptor activation therapy
- heart failure
- reduced ejection fraction
- cardiac resynchronization therapy
- device therapy
- cardiology & cardiovascular medicine clinical trials
- interventional techniques & devices
- © 2015 SAGE Publications
Tools
BAT Improves Clinical Status Preferentially in Patients Not Undergoing CRT
Permalink:
Table of contents
Cited By...
- No citing articles found.